Marianne Ashford

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6410443/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Advanced Drug Delivery Reviews, 2017, 108, 25-38.	13.7	881
2	Multiplexing Spheroid Volume, Resazurin and Acid Phosphatase Viability Assays for High-Throughput Screening of Tumour Spheroids and Stem Cell Neurospheres. PLoS ONE, 2014, 9, e103817.	2.5	176
3	Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo. Science Translational Medicine, 2016, 8, 325ra17.	12.4	171
4	Cancer nanomedicine: is targeting our target?. Nature Reviews Materials, 2016, 1, .	48.7	154
5	Penetration and Uptake of Nanoparticles in 3D Tumor Spheroids. Bioconjugate Chemistry, 2019, 30, 1371-1384.	3.6	141
6	Chitosan/Hyaluronic Acid Nanoparticles: Rational Design Revisited for RNA Delivery. Molecular Pharmaceutics, 2017, 14, 2422-2436.	4.6	114
7	Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy. Communications Biology, 2021, 4, 112.	4.4	63
8	A novel in situ hydrophobic ion pairing (HIP) formulation strategy for clinical product selection of a nanoparticle drug delivery system. Journal of Controlled Release, 2016, 229, 106-119.	9.9	59
9	Endocytic Profiling of Cancer Cell Models Reveals Critical Factors Influencing LNP-Mediated mRNA Delivery and Protein Expression. Molecular Therapy, 2019, 27, 1950-1962.	8.2	58
10	In vitro co-culture model of medulloblastoma and human neural stem cells for drug delivery assessment. Journal of Biotechnology, 2015, 205, 3-13.	3.8	52
11	Nanomanufacturing through microfluidic-assisted nanoprecipitation: Advanced analytics and structure-activity relationships. International Journal of Pharmaceutics, 2017, 534, 97-107.	5.2	40
12	Tumour regression and improved gastrointestinal tolerability from controlled release of SN-38 from novel polyoxazoline-modified dendrimers. Journal of Controlled Release, 2017, 247, 73-85.	9.9	32
13	Effect of complexing lipids on cellular uptake and expression of messenger RNA in human skin explants. Journal of Controlled Release, 2021, 330, 1250-1261.	9.9	28
14	Tumour-on-chip microfluidic platform for assessment of drug pharmacokinetics and treatment response. Communications Biology, 2021, 4, 1001.	4.4	28
15	Microfluidic-assisted nanoprecipitation of (PEGylated) poly (d,l-lactic acid-co-caprolactone): Effect of macromolecular and microfluidic parameters on particle size and paclitaxel encapsulation. International Journal of Pharmaceutics, 2018, 548, 530-539.	5.2	27
16	Synthesis and Characterization of Dendrimer-Based Polysarcosine Star Polymers: Well-Defined, Versatile Platforms Designed for Drug-Delivery Applications. Biomacromolecules, 2020, 21, 3332-3341.	5.4	26
17	Microfluidic-assisted preparation of RGD-decorated nanoparticles: exploring integrin-facilitated uptake in cancer cell lines. Scientific Reports, 2020, 10, 14505.	3.3	25
18	Amphiphilic tri- and tetra-block co-polymers combining versatile functionality with facile assembly into cytocompatible nanoparticles. Biomaterials Science, 2019, 7, 3832-3845	5.4	18

MARIANNE ASHFORD

#	Article	IF	CITATIONS
19	Nucleic Acid-Loaded Lipid Nanoparticle Interactions with Model Endosomal Membranes. ACS Applied Materials & Interfaces, 2022, 14, 30371-30384.	8.0	18
20	Highway to Success—Developing Advanced Polymer Therapeutics. Advanced Therapeutics, 2021, 4, 2000285.	3.2	16
21	Enhanced Intraliposomal Metallic Nanoparticle Payload Capacity Using Microfluidic-Assisted Self-Assembly. Langmuir, 2019, 35, 13318-13331.	3.5	14
22	High-resolution 3D visualization of nanomedicine distribution in tumors. Theranostics, 2020, 10, 880-897.	10.0	13
23	Multi-modal molecular imaging maps the correlation between tumor microenvironments and nanomedicine distribution. Theranostics, 2022, 12, 2162-2174.	10.0	9
24	Functionalized Block Coâ€Polymer Proâ€Drug Nanoparticles with Antiâ€Cancer Efficacy in 3D Spheroids and in an Orthotopic Triple Negative Breast Cancer Model. Advanced Therapeutics, 2021, 4, 2000103.	3.2	6
25	Investigating the properties of <scp>l</scp> -lysine dendrimers through physico-chemical characterisation techniques and atomistic molecular dynamics simulations. Polymer Chemistry, 2022, 13, 2626-2636.	3.9	6
26	Evaluating liver uptake and distribution of different poly(2-methyl-2-oxazoline) modified lysine dendrimers following intravenous administration. Biomaterials Science, 2019, 7, 3418-3424.	5.4	4
27	Drug delivery—the increasing momentum. Drug Delivery and Translational Research, 2020, 10, 1888-1894.	5.8	4
28	Subcutaneous delivery of a dendrimer-BH3 mimetic improves lymphatic uptake and survival in lymphoma. Journal of Controlled Release, 2022, 348, 420-430.	9.9	4
29	Synthesis, characterisation and evaluation of hyperbranched <i>N</i> -(2-hydroxypropyl) methacrylamides for transport and delivery in pancreatic cell lines <i>in vitro</i> and <i>in vivo</i> . Biomaterials Science, 2022, 10, 2328-2344.	5.4	3
30	Abstract 1718: Design and optimization of a dendrimer-conjugated dual Bcl-2/Bcl-xL inhibitor, AZD0466, with improved therapeutic index. Cancer Research, 2020, 80, 1718-1718.	0.9	2
31	Quantitative Evaluation of Dendritic Nanoparticles in Mice: Biodistribution Dynamics and Downstream Tumor Efficacy Outcomes. Molecular Pharmaceutics, 2022, 19, 172-187.	4.6	0